Implementing prognostic and predictive biomarkers in CRC clinical trials

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Protein and genomic markers have improved prognostic information and treatment prediction for colorectal cancer (CRC) over the last 20 years.
• KRAS was the first biomarker incorporated into clinical practice for CRC, guiding systemic and targeted therapy decisions.
• Microarray-based gene-expression profiling has identified prognostic and predictive signatures in CRC, but faces challenges in study design, reproducibility, and interpretation.

Purpose of the Study:

• To review the clinical application of various prognostic and predictive protein and genomic markers in colorectal cancer.
• To discuss the challenges associated with microarray-based gene-expression profiling in CRC research.
• To explore pathways for the clinical validation and implementation of genomic biomarkers in CRC.

Main Methods:

• Review of published literature on protein and genomic markers in colorectal cancer.
• Analysis of challenges in microarray-based gene-expression profiling studies.
• Discussion of clinical trial designs for biomarker validation.

Main Results:

• KRAS is an established biomarker in CRC clinical practice.
• Numerous prognostic and predictive genomic signatures have been identified but are not yet in routine use.
• Challenges in study design, reproducibility, and interpretation hinder the clinical adoption of genomic signatures.

Conclusions:

• Despite identified challenges, novel adaptive clinical trial designs offer a route for validating genomic markers.
• Prospective randomized trials incorporating genomic prognostic/predictive markers are crucial for clinical validation.
• Successful validation may facilitate the integration of these biomarkers into routine colorectal cancer medical practice.